ACTIV-4C

 A Multicenter, Adaptive, Prospective, Randomized Trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (ACTIV-4c)

Primary objective is to determine the most effective and safe antithrombotic strategy to prevent the composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality by 30 days following discharge from the hospital